October 3, 2023

Press Release

European Federation of Pharmaceutical Industries and Associations (EFPIA Japan)
EFPIA Japan Announces Winners for 6th “PASE AWARD”
Patient Organization Support Program
TOKYO – 3rd October 2023 - The European Federation of Pharmaceutical Industries andAssociations (EFPIA Japan, Chair: Takahiko Iwaya) announced the following award winners
for the 6th PASE AWARD, a Patient Advocacy Support program by EFPIA Japan.
PASE AWARD is a patient organization support program established in 2017 with the goal ofencouraging patient group activities in Japan and developing a better healthcare environment
surrounding patients by reflecting patients’ voices appropriately in the healthcare system.
6th PASE AWARD Winners
AwardGrandAward

Name of the award
organization
General
IncorporatedAssociation
CSR ProjectGrandAward

Non-profit
Organization

Awarded Implementation Plan [*]

Grant
JPY

Universal cancer education throughmultilingual and multicultural learningmaterials, promotion of international
exchange

500,000

Improving quality of life in neuromyelitis
optica patients by visualization

500,000

Developing an ‘Intractable Disease
Persona Workshop’ to infer and think
about the background and problems
surrounding those affected

500,000

Questionnaire survey of female CML
patients who wish to conceive and have achild and raising awareness of the issue

150,000

Production and distribution of ribbon
badges to be worn by people with aphasia

150,000

NMOSD JapanGrandAward

Non-profit
Organization
Ryoiku World

Honor
AwardGeneral
Incorporated
Association
Team CML @Japan

Honor
Award

Non-profit
Organization
Japan Aphasia Peer
CirclePreviously, the PASE AWARD was intended for officially registered non-profit patientorganizations such as incorporated associations, foundations, and non-profit organizations.
This year, EFPIA Japan has expanded the scope of applications to unincorporated patientorganizations and called for entries under the theme of “improving the health and quality oflife of patients” and received applications from a total of 20 organizations. After initial reviews

in writing and final reviews through presentations and questions and answers, threeorganizations were selected for the Grand Award, and two organizations were selected for
the Honor Award.
The selection committee members for the final review are as follows.
Mr. Takeo Nakayama (Kyoto University Faculty of Medicine, Professor of Health
Informatics)
Mr. Takahiko Iwaya, EFPIA Japan Chair (Sanofi K.K.)
Mr. Paul Lirette, EFPIA Japan Board Member (GlaxoSmithKline K.K.)
Ms. Yuko Kidoguchi, EFPIA Japan Communications Committee Chair (AstraZeneca K.K.)
Mr. Daisuke Uchida, EFPIA Japan Governance and Legal Committee Chair (Sanofi K.K.)
Takahiko Iwaya, Chair of EFPIA Japan, commented, "I would like to thank all the patientorganizations that applied for the 6th PASE AWARD. Patient organizations play a wide
range of roles in shaping a better treatment environment for patients, and EFPIA Japan willcontinue to collaborate and interact with patient organizations.”
The Awards Ceremony will be held at the Imperial Hotel on October 4th, and the organizations
that receive the Grand Award will be asked to present their plan at the Ceremony.
About the EFPIA Japan Patient Association Program “PASE AWARD”
EFPIA Japan works with patients to support opportunities and activities that address patientneeds and policy proposals. The PASE (Patient Advocacy Support by EFPIA Japan) AWARD
was established in 2017 to encourage the patient group activities in Japan. Over the past 6years, a total of 106 organizations have applied for a wide range of activity plans, and weprovide a total of 1.8 million yen in grants to three organizations for Grand Awards and twoorganizations for Honor Awards.
See the link for more information about PASE.
http://efpia.jp/pase/index.html
About EFPIA Japan (http://efpia.jp/)
Established in April 2002, EFPIA Japan represents 23 R&D-based European pharmaceuticalcompanies operating in Japan. In 2022, combined sales from the member companies
accounted for roughly 31% of the pharmaceutical market in Japan. The mission of EFPIA
Japan is to “Contribute to healthcare and patients in Japan through the early introduction ofinnovative medicines and vaccines”. EFPIA Japan aims to strengthen dialogue with decisionmakers in order to improve Japanese healthcare for all.
About EFPIA (European Federation of Pharmaceutical Industries and Associations)(http://www.efpia.eu)
The European Federation of Pharmaceutical Industries and Associations (EFPIA)
represents the biopharmaceutical industry operating in Europe. Through its direct
membership of 37 national associations, 40 leading pharmaceutical companies, and a
growing number of small and medium sized enterprises (SMEs), EFPIA’s mission is tocreate a collaborative environment that enables our members to innovate, discover,develop, and deliver new therapies and vaccines for people across Europe, as well as
contribute to the European economy.
2Contact:Hitoshi Fujita
EFPIA Japan Communications Committee〒105-6333
1-23-1 Toranomon 1, Minato-ku, TokyoToranomon Hills Mori Tower
Novartis Pharma K.K.
TEL: 090-9837-4326
Mail: hitoshi.fujita@novartis.com

Naomi Sakai (Person in charge of PASE)
EFPIA Japan Patient Committee〒141-6017
2-1-1 Osaki, Shinagawa-ku, Tokyo
ThinkPark Tower
Nippon Boehringer Ingelheim Co., Ltd.
TEL: 03-6417-2489
Mail: naomi.sakai@boehringer-ingelheim.com